
Fig A1. PRISMA flow chart of the eligible Cochrane reviews



179 forest plots/meta-analyses




Table A1. Description of the 139 meta-analyses with mortality outcomes

					Trials from less	Trials from more	
					developed countries,	developed countries,	All trials,
CDSR	Condition	Experimental intervention	Control intervention	Outcome	N	N	N
CDSK	Prevention of	intervention	intervention	Outcome			
	neonatal respiratory						
	disease for women			Death prior to	1	5	6
CD000019	at risk of preterm	Thyrotropin-releasing hormone plus steroids	Steroids alone	hospital discharge	1	5	6
CD000017	Anticoagulants for	normone plus steroids	Steroids alone	Death from all			
	acute ischaemic			causes at final	2	6	8
CD000024	stroke	Anticoagulant	Placebo	follow up			
	Antiplatelet therapy for acute ischaemic		Placebo or no	Deaths from all causes during	1	7	8
CD000029	stroke	Antiplatelet	treatment	follow up		,	
	Interventions for	•					
	deliberately altering	DI I		Case fatality	2	7	9
CD000039	blood pressure in acute stroke	Blood pressure lowering therapy	Placebo	within one month	2	/	9
CD000037	Corticosteroids for	lowering therapy	1 laccoo	month			
	acute ischaemic				1	6	7
CD000064	stroke	Corticosteroids	Placebo	All deaths			
	Fibrinogen depleting agents for			Death from all			
	acute ischaemic	Fibrinogen depleting		causes at end of	1	4	5
CD000091	stroke	agents	Placebo	follow up			
	Mother-to-child		DI I		2	1	3
CD000102	transmission of HIV infection.	Any zidovudine	Placebo or no treatment	Stillbirth	2	1	3
CD000102	inicetion.	Hospitalisation for	treatment	Sumontii	4	3	7
CD000110	Multiple pregnancy	bed rest	Routine care	Perinatal death			
	Peripheral arterial						
CD000123	disease of the lower limb	Lipid-lowering regimens	Placebo or usual care	All-cause mortality	2	4	6
CD000123	Acute ischaemic	Pentoxifylline or	Care	Case fatality	2	2	4
CD000162	stroke	analogue	Placebo	early			
	Latent tuberculosis				10	4	10
CD000171	infection in HIV	Any TB drug	Placebo	Incidence of death (all cause)	12	1	13
CD000171	infected persons Acute bleeding	Somatostatin	Placebo or no	death (an cause)	7	9	16
CD000193	oesophageal varices	analogues	treatment	Mortality			
				Death by the			
	Organised inpatient (stroke unit) care for	Organizad strat-	Alternative	end of	2	14	16
CD000197	(stroke unit) care for stroke	Organised stroke unit care	service	scheduled follow up		17	10
300171	Thrombolysis for		322.230	Deaths from all			
an coort	acute ischaemic	Any thrombolytic	Placebo or no	causes during	2	23	25
CD000213	stroke Zinc	agent	intervention	follow up			
	supplementation for						
	improving		No zinc (with or				
CD000220	pregnancy and	Zinc supplementation	without	Stillbirth or	2	1	3
CD000230	infant outcome	versus	Placebo) Placebo or no	neonatal death			
			intervention or				
		Calcium antagonists +	conventional		1	2	3
	Aneurysmal	magnesium	treatment	Case fatality	1	10	1.1
CD000277	subarachnoid	Calcium antagonists	Placebo or no	Casa fatality	1	10	11
CD0002//	haemorrhage	alone	intervention or	Case fatality		1	<u> </u>

			conventional				
			treatment				
	Prevention of deep		Placebo or no		1	7	8
	vein thrombosis and pulmonary	Any heparin	intervention	Mortality			
	embolism following						
	surgery for hip		Placebo or no		1	3	4
CD000305	fractures	Physical device	intervention	Mortality			
				Mortality at 6			
				months - patients			
	Early discharge	Early discharge	Acute hospital	recovering from	1	5	6
CD000356	hospital at home	hospital at home	in-patient care	a stroke			
	Prevention of						
	infection in preterm		DI I	3.6 . 12	5	10	15
CD000361	and/or low-birth- weight infants	IVIG	Placebo or no treatment	Mortality (all causes)	3	10	13
CD000301	Prevention of	1710	treatment	causes)			
	pneumococcal			Mortality all	2	9	11
CD000422	infection in adults	Vaccination	Placebo	causes			
	Services for						
	reducing duration of hospital care for	Foulty symmouted	Conventional		1	10	11
CD000443	acute stroke patients	Early supported discharge service	care	Death		10	
СВОООТТЗ	Prevention of	discharge service	care	Deutii			
	mortality and short-						
	and long-term						
	morbidity in very	G 1 . 1	DI I	D 41.1.6	1	5	6
CD000501	low birth-weight infants	Supplemental vitamin A	Placebo or no supplementation	Death before one month	1	3	O
CD000301	Inhaled nitric oxide	A	supplementation	one monu			
	for respiratory		Placebo or				
	failure in preterm		conventional	Death before	2	7	9
CD000509	infants	Inhaled nitric oxide	treatment	discharge			
		Reduced number of antenatal care	Standard antenatal care		3	2	5
CD000934	Low-risk pregnancy	visits/goal oriented	visits	Perinatal death	3	2	
CD000754	Preterm rupture of	Transabdominal	No	1 Cimatai acam	1	1	2
CD000942	membranes	amnioinfusion	amnioinfusion	Neonatal death			
	Tamoxifen for						
GD 004024	hepatocellular		Placebo or best	All cause	1	8	9
CD001024	carcinoma	Tamoxifen	supportive care	mortality			
	Calcium supplementation						
	during pregnancy						
	for preventing			Stillbirth or			
	hypertensive			death before			10
CD001050	disorders and	Routine calcium	Disasta	discharge from	6	4	10
CD001059	related problems	supplementation Prophylactic	Placebo	hospital	1		
	Abdominal	abdominal	Dummy				
	decompression in	decompression in	decompression	Perinatal	1	1	2
CD001062	normal pregnancy	pregnancy	or no treatment	mortality			
	Treatment of sepsis,		DI I	A 11	9	20	20
CD001090	severe sepsis and septic shock	IVIG	Placebo or no intervention	All-cause mortality	9	30	39
CD001090	Nerve blocks for hip	1410	mei venuon	mortality	1	7	8
CD001159	fractures	Nerve block versus	No block	Mortality		,	
	Proven infection in		Placebo or no	Mortality from	5	2	7
	neonates	IVIG	intervention	any cause			
	Suspected infection		Placebo or no	Mortality from	5	2	7
CD001239	in neonates	IVIG	intervention	any cause			
	Antiplatelet agents			A 11	1	4	5
CD001272	for intermittent claudication	Antiplatelet agent	Placebo	All cause mortality	1	4)
CD001212	ciaudication	mupiatetet agetit	1 140000	mortanty	1	I	1

	Tuberculosis						
	prevention in non-						
	HIV infected				2	3	5
CD001363	persons	Isoniazid	Placebo	Total deaths			
CD001303	Corticosteroids for	Isomazia	1 laceso	Total deaths			
	Guillain-Barré				3	4	7
CD001446	syndrome	Corticosteroids	Placebo	Death			
	Treatment of				6	1	7
CD001479	measles in children	Vitamin A	Placebo	Mortality			
CDOOTITY	Preoperative Preoperative	v italiiii 11	Taccoo	Wiorunty			
	chemotherapy for						
	resectable thoracic	Preoperative		Postoperative	3	5	8
CD001556	esophageal cancer	chemotherapy	Surgery alone	deaths			
	Medical day	••					
	hospital care for the						
	elderly versus						
	alternative forms of		Non-day	Death by the	1	12	13
CD001730	care	Day hospital care	hospital care	end of follow up			
	Coronary Heart	Exercise-based			1	15	16
CD001800	Disease	rehabilitation	Usual care	Total mortality			
	Treatment of acute	Third generation	Conventional		10	9	19
CD001832	bacterial meningitis	cephalosporins	therapy	Death			
					1	16	17
CD001841	Hypertension	Thiazide	Placebo	Total Mortality			
	Surfactant for						
	meconium						
	aspiration syndrome						
	in full term/near		Placebo or no		2	2	4
CD002054	term infants	Surfactant therapy	therapy	Mortality			
	Prophylactic						
	anastomotic	B 1 1 2			1	_	
GD002100	drainage for	Prophylactic	37 1 1	3.6 . 12.	1	5	6
CD002100	colorectal surgery Non-ST segment	anastomotic drainage	No drainage	Mortality			
	elevation acute	Intravenous IIb/IIIa	Placebo or usual	6-month	3	19	22
CD002130	coronary syndromes	blockers during PCI	care	mortality	3	17	
CD002130	Postoperative Postoperative	blockers during i ei	care	mortanty			
	radiotherapy (RT)						
	for non-small cell	Surgery plus post-			2	8	10
CD002142	lung cancer	operative RT	Surgery alone	Mortality			
	Acute esophageal	•		j	2	3	5
CD002147	variceal hemorrhage	Terlipressin	Vasopressin	Mortality			
	<u> </u>	Methadone	No methadone	j			
		maintenance	maintenance		1	3	4
CD002209	Opioid dependence	treatment	treatment	Mortality			
	Treatment of severe		Placebo or				
	sepsis and septic		supportive	28-day all-cause	3	16	19
CD002243	shock	Corticosteroids	treatment	mortality			
	Chronic obstructive	Phosphodiesterase 4			1	8	9
CD002309	pulmonary disease	inhibitors	Placebo	Mortality			
	Kangaroo mother						
	care versus				7		
GD002551	conventional	77	Conventional	Mortality at	7	2	9
CD002771	neonatal care	Kangaroo mother care	neonatal care	latest follow up		ļ	
	Prevent ion of						
	thrombosis and						
	catheter occlusion						
	in neonates with						
	peripherally placed						
	percutaneous central				1	2	3
CD002772	venous catheters	Heparin	No heparin	Mortality			
	Acute respiratory	•		ĺ			
	distress syndrome		Placebo or no	Longest follow	2	12	14
CD002787	and acute lung	Inhaled nitric oxide	intervention	up mortality			

	injury in children						
	and adults						
	Blood-pressure						40
GD002020	lowing in acute	Blood pressure	Placebo or no	Death at end of	3	37	40
CD002839	stroke Diarrhoea	lowering therapy	intervention	trial	2	2	4
CD002848	prevention	Rotavirus vaccine	Placebo	All-cause death	2	2	4
CD002040	prevention	Rotavirus vacenie	Tuccoo	7111 Cadse death	1	1	2
	Mild to moderate			Maternal death			
	hypertension during		Placebo or no	Perinatal	1	12	13
CD002863	pregnancy	Beta-blocker	intervention	mortality			
	Cirrhotic patients						
	with upper gastrointestinal		Placebo or no		5	7	12
CD002907	bleeding	Antibiotic prophylaxis	intervention	Mortality			
		Immunosuppressive		All-cause	1	4	5
CD002922	Lupus nephritis	agent plus steroids	Steroids alone	mortality			
	Smoking cessation for the secondary						
	prevention of						
	coronary heart		Continued		1	18	19
CD003041	disease	Ceased smoking	smoking	Total deaths			
	G-CSF and GM-			A 11			
	CSF for treating or preventing neonatal			All cause mortality to 28	2	3	5
CD003066	infections	CSF versus	Control	days	_		
	Elderly people at			,			
GD 002200	risk from	Oral protein and	.	3.6	1	40	41
CD003288	malnutrition Cooling for	energy	Routine care	Mortality			
	newborns with			Mortality by			
	hypoxic ischaemic	Therapeutic		method of	2	5	7
CD003311	encephalopathy	hypothermia	Standard care	cooling			
			Placebo or no	Death during whole follow-up	6	5	11
CD003317	Acute stroke	Acupuncture	intervention	period			11
	Prevention of			F			
	invasive fungal						
	infection in very low birth weight	Oral/topical non- absorbed antifungal	Placebo or		2	1	3
CD003478	infants	prophylaxis	nothing	Mortality		1	
	Ibuprofen for the	p py	8				
	treatment of patent						
	ductus arteriosus in preterm and/or low			All cause	4	4	8
CD003481	birth weight infants	Ibuprofen	Indomethacin	mortality	-	-	
	Meconium			Mortality before			
	aspiration syndrome			hospital	1	1	2
CD003485	in newborn infants	Steroid	Placebo	discharge		1	
	Support systems versus standard		Standard		1	11	12
CD003628	medical therapy	Support systems	medical therapy	Mortality		<u> </u>	
	Prevention of oral						
	candidiasis for	Denos obserts d'es	Dlaceba		1	2	3
CD003807	patients with cancer receiving treatment	Drugs absorbed from GI tract	Placebo or no treatment	Death	1		3
22 303007	Prophylactic Prophylactic	22 4440				1	
	systemic antifungal						
	agents to prevent						
	mortality and morbidity in very			Death prior to			
	low birth weight	Systemic antifungal	Placebo or no	hospital	1	3	4
CD003850	infants	agent	treatment	discharge			
	Interleukin 2	ша	DI. I	M. A. President	5	15	20
CD003897	receptor antagonists for kidney	IL2 receptor antagonists	Placebo or no treatment	Mortality at 1	5	15	20
CD00309/	101 Kluffey	antagomsts	ucamieni	year	<u>I</u>	I	

	transplant recipients						
	Repeat doses of						
	prenatal						
	corticosteroids for						
	women at risk of						
	preterm birth for						
	improving neonatal	Repeat doses of	Single course of		1	6	7
CD003935	health outcomes	corticosteroids	corticosteroids	Neonatal death			
	Thymic peptides for						
	treatment of cancer	Synthetic thymic	Placebo or no		1	3	4
CD003993	patients	peptides	treatment	Overall survival	_		
					2	12	14
				Overall survival			
		TT' 1 1		Treatment			
	Aggressive Non-	High-dose		related			
	Hodgkin Lymphoma (NHL)	chemotherapy with autologous stem cell	Conventional	mortality/ Mortality during	2	12	14
CD004024	in adults	transplantation	chemotherapy	treatment	2	12	14
CD004024	Vitamin E	transplantation	Chemotherapy	treatment			
	supplementation in		Placebo or no		1	1	2
CD004069	pregnancy	Vitamin E	treatment	Stillbirth			
	Vitamin C						
	supplementation in		Placebo or no		2	1	3
CD004072	pregnancy	Vitamin C	treatment	Stillbirth			
	Non-invasive						
	positive pressure						
	ventilation (NPPV)						
	for treatment of						
	respiratory failure due to exacerbations						
	of chronic						
	obstructive	NPPV +Usual	Usual medical		3	6	9
CD004104	pulmonary disease	medical care	care	Mortality			
CD004104	Prevention Prevention	medicar care	cure	Wiortanty			
	gastrointestinal				5	8	13
CD004183	cancers	Antioxidants	Placebo	Mortality			
	Ibuprofen for the						
	prevention of patent			Neonatal			
	ductus arteriosus in			mortality			
GD004010	preterm and/or low	П С	Placebo or no	(during first 28	1	2	3
CD004213	birth weight infants	Ibuprofen	intervention	days of life)			
	Antioxidants for				1	3	4
CD004227	preventing pre- eclampsia	Any antioxidants	Placebo	Any baby death	1		-
CD004221	Ethamsylate for the	2 my andoxidalits	1 10000	2 my baby ucalii			
	prevention of						
	morbidity and						
	mortality in preterm			Mortality to			
	or very low birth			hospital	3	4	7
CD004343	weight infants	Ethamsylate	Placebo	discharge			
	Prophylaxis for						
	bacterial infections						
	in afebrile						
	neutropenic patients		DI I	4.11		20	41
CD004296	following	Ovinclana	Placebo or no	All-cause	2	39	41
CD004386	chemotherapy	Quinolone	intervention	mortality			
	Antenatal corticosteroids for						
	accelerating fetal						
	lung maturation for						
	women at risk of		Placebo or no	Fetal and	3	10	13
CD004454	preterm birth	Corticosteroids	intervention	neonatal deaths			
-	Primary	* ****	Placebo or				
	intracerebral	Glucocorticoid	standard	Death at the end	3	2	5
CD004583	haemorrhage	treatment	strategy	of follow up			

	Antiplatelet agents						
	for preventing pre-						
	eclampsia and its		Placebo or no		2	11	13
CD004659		Antimistalet egente	intervention	Perinatal deaths	2	11	
CD004039	complications	Antiplatelet agents	Intervention	Permatai deams			
	Prophylactic oral						
	betamimetics for						
	reducing preterm				1		
GD 00 4 500	birth in women with			Neonatal	1	2	3
CD004733	a twin pregnancy	Oral betamimetic	Placebo	mortality			
	Primary prevention						
	of cryptococcal						
	disease in adults			Overall	2	2	4
CD004773	with HIV	Antifungals	Placebo	mortality			
	Treatment for						
	anemia in people		Placebo plus		1	1	2
CD004776	with AIDS.	Epoetin plus HAART	HAART	Death			
	Laparoscopic repair						
	for perforated peptic				2	1	3
CD004778	ulcer disease	Laparoscopic surgery	Open surgery	Mortality			
	Unresectable		1 0 3				
	hepatocellular		Placebo or no	All-cause	1	8	9
CD004787	carcinoma	TACE or TAE	intervention	mortality			
	Antibiotic						
	prophylaxis for						
	spontaneous						
	bacterial peritonitis						
	in cirrhotic patients						
	with ascites, without						
	gastro-intestinal		Placebo or no		1	6	7
CD004791	bleeding	Antibiotic prophylaxis	treatment	Mortality	•		'
CD004791		Antibiotic propriyraxis	treatment	Williamy			
	Early erythropoietin						
	(EPO) for						
	preventing red						
	blood cell			3.6 . 11. 1			
	transfusion in		D1 1	Mortality during	3	12	15
GD004062	preterm and/or low		Placebo or no	initial hospital	3	12	13
CD004863	birth weight infants	Early erythropoietin	treatment	stay (all causes)			
	Late initiation of						
	EPO (8-28 days) vs						
	placebo or no						
	intervention for						
	preventing red						
	blood cell			All-cause			
	transfusion in			mortality during		1.1	1.4
	preterm and/or low		Placebo or no	initial hospital	3	11	14
CD004868	birth weight infants	Late erythropoietin	treatment	stay			
	Prevention						
	meningitis in						
	patients with basilar		Placebo or no	All-cause	2	2	4
CD004884	skull fractures	Antibiotic prophylaxis	treatment	mortality			
	Multiple-		No				
	micronutrient		supplements,				
	supplementation for		placebo or less				
	women during	Multiple	than two	Perinatal	6	1	7
CD004905	pregnancy	micronutrients	micronutrients	mortality			<u> </u>
	Preventing fungal						
	infections in non-						
	neutropenic		Placebo/no		1	9	10
CD004920	critically ill patients	Systemic antifungal	antifungal	Mortality			
	Improving birth		<u> </u>				
	outcomes for						
	women at or beyond		Expectant		3	7	10
CD004945	term	Labour induction	management	Perinatal death			
22 30 .7 10	Preventing vaccine-	madelion					
1		Pneumococcal	Placebo or no	All-cause	3	2	5
	type invasive						
CD004977	type invasive pneumococcal	vaccine	intervention	mortality			

	1 1 1 7 7	Т	1	1	ı	1	_
	disease and X-ray						
	defined pneumonia						
	in children less than						
	two years of age						
	Terlipressin for						
	hepatorenal	Octreotide or			2	2	4
CD005162	syndrome	terlipressin	Placebo	Mortality			
	Brief interventions	1					
	for heavy alcohol		Assessment/no-				
	users admitted to		intervention or				
			standard		2	5	7
GD005101	general hospital	D. C.		D 4	2	3	,
CD005191	wards	Brief interventions	treatment	Death			
					1	7	8
	Metastatic			Overall survival			
	malignant	Chemoimmunotherap		Treatment-	2	9	11
CD005413	melanoma	у	Chemotherapy	related mortality			
CD003413	Proton pump	J	Chemotherapy	Teluted mortanty			
	inhibitor treatment			M . 11. 20			
	prior to endoscopic			Mortality - 30			
	diagnosis in upper			days or at point		_	_
	gastrointestinal	Proton pump	Placebo or no	closest to 30	2	2	4
CD005415	bleeding	inhibitors	intervention	days			
	Obstructive	Pre-operative biliary			3	2	5
CD005444	iaundice	drainage	Direct surgery	Mortality			
22303111	Prevention of						
	necrotizing			All cause		1	
			DI I		3	7	10
	enterocolitis in		Placebo or no	neonatal	3	/	10
CD005496	preterm infants.	Probiotics	intervention	mortality			
	ERCP in patients						
	with						
	pancreaticobiliary						
	malignancy, prior to		Without	Overall	1	1	2
CD006001	surgery	With stenting	stenting	mortality			
	Electronic fetal	······································					
	monitoring for fetal						
	assessment during	Continuous	Intermittent		1	11	12
CD00C0CC	_		auscultation	D	1	11	12
CD006066	labour	cardiotocography	auscultation	Perinatal death			
	Routine abdominal						
	drainage for			Mortality at			_
	uncomplicated liver			maximal	2	3	5
CD006232	resection	Drain	No drain	follow-up			
	Oral cavity and						
	oropharyngeal	Altered fractionation	Conventional		1	13	14
CD006387	cancer	radiotherapy	radiotherapy	Total mortality			
2200000	Immunoglobulin	Tuarouterupy	radioalerapy	1 otal mortane			
	prophylaxis in						
		Dolymolont					
	hematological	Polyvalent				1	
	malignancies and	immunoglobulins or			1	1,1	12
	hematopoietic stem	hyperimmune CMV-	Placebo / no	All-cause	1	11	12
CD006501	cell transplantation	IVIG	intervention	mortality			
	Stem cell treatment					1	
	for acute		No bone			1	
	myocardial	Bone marrow-derived	marrow-derived		1	3	4
CD006536	infarction	stem cells	stem cells	Mortality		1	
				All-cause		1	1
			Placebo or no	mortality at 10	1	18	19
		Pote blookers		-	_		1/
		Beta-blockers	treatment	days		1	
				All-cause	1	1.5	16
	Early treatment with	Calcium-channel	Placebo or no	mortality at 10	1	15	16
	anti-hypertensive	blockers	treatment	days			
	drugs in patients		1	All-cause	_	_]
	with an acute		Placebo or no	mortality at 10	1	14	15
CD006743	cardiovascular event	Nitrates	treatment	days			
	Statins for acute		Placebo/ usual	Death from all	2	8	10
CD006870		Stating			~		10
L CD0000/0	coronary syndrome	Statins	care	causes		1	

	Infantis	T				1	1
	Infectious complications in						
	haemodialysis						
	patients with central	Topical antimicrobial	No ointment/	All-cause	1	2	3
CD006894	venous catheters	ointment	placebo	mortality			
== 300071	Reduction of the		P				
	duration of						
	mechanical						
	ventilation in		Non-				
	critically ill adult		protocolized		1	8	9
CD006904	patients	Protocolized weaning	weaning	Mortality			
	Ultrasound for fetal	C-1+:11	Routine or revealed				
	assessment in early	Selective or concealed ultrasound in early	ultrasound in		2	8	10
CD007058	pregnancy	pregnancy	early pregnancy	Perinatal death		o o	10
CB007030	Multidisciplinary	pregnancy	early programey	1 cilitatai deatii			
	rehabilitation for	Multidisciplinary		Mortality (end			
	older people with	inpatient		of scheduled	1	10	11
CD007125	hip fractures	rehabilitation	Usual care	follow-up)			
			Centre-based				
ap.co=1==	Coronary heart	Home-based cardiac	cardiac	3.6	1	3	4
CD007130	disease	rehabilitation	rehabilitation	Mortality			
	Antioxidant						
	supplements for prevention of						
	mortality in healthy						
	participants and						
	patients with		Placebo or no		7	58	65
CD007176	various diseases	Antioxidants	intervention	Mortality			
	Structured			•			
	telephone support or						
	telemonitoring						
	programmes for	G 1. 1 1		A 11	1	13	14
CD007228	patients with chronic heart failure	Structured telephone	Usual care	All-cause mortality	1	13	14
CD007228	chronic heart famure	support	Placebo or	Шопанту			
	Pentoxifylline for		standard	All-cause	2	3	5
CD007339	alcoholic hepatitis	Pentoxifylline	treatment	mortality			
	Intra-aortic balloon			j			
	pump						
	counterpulsation for						
	myocardial						
	infarction	Intra-aortic balloon	No intra-aortic	All-cause in-	1	3	1
CD007209	complicated by cardiogenic shock	pump counterpulsation	balloon pump counterpulsation	hospital mortality rates	1	3	4
CD007398	Vascular occlusion	counterpulsation	counterpulsation	mortality rates	1	1	
	for elective liver		No vascular		2	3	5
CD007530	resections	Vascular occlusion	occlusion	Mortality			
	Rehabilitation	***		,			
	interventions for						
	improving physical						
	and psychosocial						
	functioning after hip	Smariali-t 1 1		Montel!: (2	1	1	2
CD007624	fracture in older people	Specialist nurse led care	Usual care	Mortality at 3 months	1	1	
CD007024	Antioxidant	care	Osuai Cale	monuis		1	
	supplements for		Placebo or no	All-cause	1	6	7
CD007749	liver diseases	Antioxidants	intervention	mortality			
	Community-based			·			
	intervention						
	packages for						
	reducing maternal						
	and neonatal						
	morbidity and	Community L		Noon-t-1	12	1	13
CD007754	mortality and improving neonatal	Community-based intervention	Standard care	Neonatal mortality	12	1	13
CD001134	improving neonatal	mer vention	Standard Care	mortanty	l	<u> </u>	1

	outcomes.						
	Statins for people						
	with chronic kidney		DI 1			1.5	21
CD007784	disease not	C4-4:	Placebo or no	All-cause	6	15	21
CD007784	requiring dialysis	Statins	treatment	mortality			
	Monitoring haemotherapy						
	versus usual care in	Thrombelastography	Routine				
	patients with	or	coagulation	Longest follow-	2	3	5
CD007871	massive transfusion	thromboelastometry	tests	up mortality			
	Prophylactic	,	Standard				
	phototherapy for		treatment or no				
	preventing jaundice		use of				
	in preterm or low	Prophylactic	prophylactic	All-cause	1	3	4
CD007966	birth weight infants	phototherapy	phototherapy	mortality			
	Secondary						
	prevention of vascular events after			D41. f			
	stroke of arterial			Death from any cause during	1	1	2
CD008076	origin	Cilostazol in patients	Aspirin	follow-up	1	1	2
CD000070	Prevention and	enostazor in patients	71351111	ionow up			
	treatment of						
	infectious						
	complications in						
	patients with acute			All-cause		10	
GD 000000	myelogenous	Colony-stimulating	Placebo or no	mortality at the	1	13	14
CD008238	leukemia	factors	treatment	end of follow up			
	Somatostatin	G		D. C. C.	1	15	16
CD008370	analogues for pancreatic surgery	Somatostatin analogues	No intervention	Perioperative mortality	1	13	10
CD008370	pancieane surgery	analogues	140 IIIIervention	Mortality at the		+	
				end of the			
				follow-up	2	1	3
CD008409	Brain injury	Progesterone	Placebo	period			
	, ,				17	3	20
CD008521	Rotavirus diarrhoea	Rotarix	Placebo	All-cause death			
	Probiotics for						
	patients with						
	hepatic		Placebo or no	All cause	1	1	2
CD008716	encephalopathy	Probiotic	intervention	mortality			

BCG: Bacille Calmett-Guerin vaccine; CDSR: Cochrane Database of Systematic

Reviews; HIV: human immunodeficiency; IVIG: intravenous immunoglobulin

Table A2. Baseline risks in the control groups. Shown are the risks for the topics where differences in effect sizes between less developed countries and more developed countries were beyond chance.

			Baseline risk in control groups in	Baseline risk in control groups in	
Condition			more developed	less developed	P for differences
Intervention	Intervention*	Outcome	countries (%)	countries %)	in baseline risk
Antenatal					
prevention in					
preterm birth		Fetal and			
(CD004454)	Corticosteroids	neonatal deaths	16 (95% CI 12-20)	33 (95% CI 9-63)	< 0.001
Antioxidant					
supplements for					
prevention of					
various diseases					
(CD007176)	Antioxidants	Mortality	8 (95% CI 6-10)	4 (95% CI 2-8)	< 0.001
Multiple					
pregnancy	Hospitalization				
(CD000110)	for bed rest	Perinatal death	3 (95% CI 1-9)	5 (95% CI 2-11)	0.206
Treatment of					
sepsis and septic		All-cause			
shock		mortality at 28-			
(CD002243)	Corticosteroids	days	34 (95% CI 26-44)	76 (95% CI 56-92)	< 0.001
Prevention of GI					
cancers					
(CD004183)	Antioxidants	Mortality	12 (95% CI 6-21)	5 (95% CI 2-8)	< 0.001
Non-neutropenic					
critically ill					
patients	Systemic				
(CD004920)	antifungals	Mortality	28 (95% CI 20-38)	54 (95% CI 38-69)	< 0.001
Treatment of non-					
small cell lung	Surgery +				
cancer	PORT vs				
(CD002142)	surgery alone	Mortality	39 (95% CI 28-50)	31 (95% CI 16-49)	0.028
Aneurysmal					
subarachnoid	Calcium				
hemorrhage	antagonists				
(CD000277)	alone	Case fatality	17 (95% CI 11-25)	17 (95% CI 8-29)	0.990
Prevention of					
infection in					
preterm and/or					
low birth weight		A 11			
infants	IVIC.	All-cause	12 (050) (01.0.10)	10 (050) (01.0.25)	. 0.001
(CD000361)	IVIG	mortality	13 (95% CI 9-18)	19 (95% CI 8-35)	< 0.001
Unresectable					
hepatocellular		A 11			
carcinoma	TACE or TAE	All-cause	ND	NP	NP
(CD004787)		mortality	NP	INF	INF
Oral cavity and oropharyngeal	Altered fractionation				
1 00		Total mortality	NP	NP	NP
cancer (6387) Cirrhosis with	radiotherapy	Total mortality	INF	INF	INF
upper GI bleeding		Bacterial			
(CD002907)	Antibiotics	infections	43 (95% CI 36-51)	28 (95% CI 16-42)	< 0.001
(CD002907)	Allubiotics	miechons	43 (93% CI 30-31)	20 (93% CI 10-42)	< 0.001

Prevention of pre-					
eclampsia					
(CD004227)	Antioxidants	D.,	12 (050/ CL (22)	12 (050/ CL 5 22)	0.603
_ ` _ ′	Antioxidants	Pre-eclampsia	13 (95% CI 6-22)	12 (95% CI 5-23)	0.003
Prevention of pre-					
eclampsia and its	A .: 1 . 1 .	D			
complications	Antiplatelet	Proteinuric pre-	45 (050) GY 44 30)	4.5 (0.50) GY 40.00)	0.400
(CD004659)	agents	eclampsia	15 (95% CI 11-20)	16 (95% CI 10-28)	0.132
Tuberculosis					
prevention in non-		Rate of			
HIV infected		development of			
persons		active			
(CD001363)	Isoniazid	tuberculosis	2 (95% CI 1-4)	15 (95% CI 6-27)	< 0.001
Prophylactic					
systemic					
antifungal agents					
to in very low					
birth weight					
infants		Invasive fungal			
(CD003850)	Fluconazole	infection	15 (95% CI 6-27)	25 (95% CI 15-37)	0.070
Peripheral arterial			, /	,	
disease of the					
lower limb	Lipid-lower	Cardiovascular			
(CD000123)	regimens	events	15 (95% CI 8-26)	23 (95% CI 14-34)	0.081
Pneumococcal	regimens	CVCIICS	13 (75 % C1 6 26)	23 (7370 CT TT 31)	0.001
infection in adults		All-cause			
(CD000422)	Vaccination	pneumonia	9 (95% CI 6-12)	5 (95% CI 1-11)	< 0.001
Vitamin E	v accination	pheumoma	7 (75 % CI 0-12)	3 (73 /0 CI I-II)	< 0.001
supplementation		Clinical pre-			
in pregnancy	Vitamin E	-	19 (050/ CI 12 22)	22 (050/ CI 12 22)	0.481
(CD004069)	VItaliilii E	eclampsia	18 (95% CI 13-23)	22 (95% CI 13-22)	0.481
Prevention of GI		T 11 COL			
cancers		Incidence of GI	2 (050) CT 1 2)	2 (050) CT 1 ()	0.001
(CD004183)	Antioxidants	cancers	2 (95% CI 1-3)	3 (95% CI 1-6)	< 0.001
Hypertension					
during pregnancy		Caesarian			
(CD002863)	Beta-blockers	section	30 (95% CI 26-33)	35 (95% CI 25-47)	0.372
Prevention of					
infection in					
preterm and/or					
low birth weight					
infants					
(CD000361)	IVIG	Sepsis	22 (95% CI 15-29)	22 (95% CI 9-39)	0.990
Antenatal care for	Reduced				
low-risk	number of				
pregnancy	visits/goal				
(CD000934)	oriented visits	Preterm birth	NP	NP	NP
Diarrhea		Episodes of			
prevention	Rotavirus	rotavirus			
(CD002848)	vaccine	diarrhea	20 (95% CI 17-23)	22 (95% CI 12-33)	0.006
Hepatic		No recovery	Í	,	
encephalopathy		from hepatic			
(CD008716)	Probiotics	encephalopathy	91 (95% CI 66-99)	63 (95% CI 31-91)	0.092
				/	

NP, not pertinent because number of events in each arm was not available.

Table A3. Primary Binary Outcomes

			Control	
CDSR	Condition	Experimental Intervention	Intervention	Primary Binary Outcome
	Prevention of neonatal respiratory	Th		Danisata and distance
CD000010	disease for women at risk of preterm birth	Thyrotropin-releasing	Steroids alone	Respiratory distress syndrome
CD000019		hormone plus steroids	Steroids alone	Death from all causes at
CD000024	Anticoagulants for acute ischaemic stroke	Anticoagulant	Placebo	final follow up
CD000024	Antiplatelet therapy for acute	Anticoaguiant	Placebo or no	Death or dependence at end
CD000029	ischaemic stroke	Antiplatelet	treatment	of follow up
CD00002)	Interventions for deliberately	7 Hitipiatelet	treatment	of follow up
	altering blood pressure in acute	Blood pressure lowering		Case fatality within one
CD000039	stroke	therapy	Placebo	month
	Corticosteroids for acute			
CD000064	ischaemic stroke	Corticosteroids	Placebo	All deaths
				Death or disability at the
	Fibrinogen depleting agents for			end of the scheduled follow
CD000091	acute ischaemic stroke	Fibrinogen depleting agents	Placebo	up period
	Mother-to-child transmission of		Placebo or no	HIV infection status in the
CD000102	HIV infection.	Any zidovudine	treatment	child
CD000110	Multiple pregnancy	Hospitalisation for bed rest	Routine care	Low birthweight (<2500 g)
=======================================	Peripheral arterial disease of the		Placebo or usual	(2000)
CD000123	lower limb	Lipid-lowering regimens	care	Total cardiovascular events
CD000162	Acute ischaemic stroke	Pentoxifylline or analogue	Placebo	Case fatality early
GD 000171	Latent tuberculosis infection in		DI I	Incidence of death (all
CD000171	HIV infected persons	Any TB drug	Placebo	cause)
GD000102	Acute bleeding oesophageal		Placebo or no	Number failing initial
CD000193	varices	Somatostatin analogues	treatment	haemostasis
CD000107	Organised inpatient (stroke unit) care for stroke	Oid -tlit	Alternative service	Death by the end of
CD000197	Thrombolysis for acute ischaemic	Organised stroke unit care	Placebo or no	scheduled follow up Deaths from all causes
CD000213	stroke	Any thrombolytic agent	intervention	during follow up
CD000213	Zinc supplementation for	Any unomborgue agent	intervention	during follow up
	improving pregnancy and infant		No zinc (with or	
CD000230	outcome	Zinc supplementation versus	without Placebo)	Pre-term birth
02000200	Prevention of deep vein	Zine supprementation versus	Placebo or no	110 001111 011011
	thrombosis and pulmonary	Any heparin	intervention	DVT
	embolism following surgery for			
CD000305	hip fractures		Placebo or no	
CD000303	inp fractures	Dhysical davice	intervention	DVT
		Physical device Early discharge hospital at	Acute hospital in-	DVI
CD000356	Early discharge hospital at home	home	patient care	Mortality at 6 months
CD000330	Prevention of infection in preterm	nome	Placebo or no	Wortanty at 6 months
CD000361	and/or low-birth-weight infants	IVIG	treatment	Sepsis one or more episodes
22000301	Prevention of pneumococcal	1,10		Expose one of more episodes
CD000422	infection in adults	Vaccination	Placebo	Pneumonia all causes
	Services for reducing duration of			
	hospital care for acute stroke	Early supported discharge		Death or requiring
CD000443	patients	service	Conventional care	institutional care
	Prevention of mortality and short-			
	and long-term morbidity in very		Placebo or no	
CD000501	low birth-weight infants	Supplemental vitamin A	supplementation	Chronic lung disease
	Inhaled nitric oxide for		Placebo or	
GB 05	respiratory failure in preterm		conventional	
CD000509	infants	Inhaled nitric oxide	treatment	Death before discharge
		Reduced number of	G. 1 1	
CD000024		antenatal care visits/goal	Standard antenatal	D (1: a
CD000934	Low-risk pregnancy	oriented	care visits	Preterm birth
CD000042	Durtous C 1	Transabdominal	Na amaiat Cata	Namedal days
CD000942	Preterm rupture of membranes	amnioinfusion	No amnioinfusion	Neonatal death
CD001024	Tamoxifen for hepatocellular	Tamovifon	Placebo or best	All agusa mortality
CD001024	carcinoma	Tamoxifen	supportive care	All cause mortality

		1	T	
	Calcium supplementation during			
	pregnancy for preventing			
	hypertensive disorders and	Routine calcium		
CD001059	related problems	supplementation	Placebo	Pre-eclampsia
			Dummy	
	Abdominal decompression in	Prophylactic abdominal	decompression or	
CD001062	normal pregnancy	decompression in pregnancy	no treatment	Perinatal mortality
	Treatment of sepsis, severe sepsis		Placebo or no	
CD001090	and septic shock	IVIG	intervention	All-cause mortality
CD001090	and septic snock	1710	intervention	All-cause mortality
CD001159	Nerve blocks for hip fractures	Nerve block versus	No block	Mortality
	•		Placebo or no	
CD001239	Suspected infection in neonates	IVIG	intervention	Mortality from any cause
CD001237	Antiplatelet agents for	1710	Intervention	Wiortanty from any cause
CD001272	intermittent claudication	A	Placebo	A 11
CD001272		Antiplatelet agent	Piacebo	All cause mortality
	Tuberculosis prevention in non-			Rate of development of
CD001363	HIV infected persons	Isoniazid	Placebo	active tuberculosis
				Improvement by one or
	Corticosteroids for Guillain-Barré			more grades after four
CD001446	syndrome	Corticosteroids	Placebo	weeks
			DI I	
CD001479	Treatment of measles in children	Vitamin A	Placebo	Mortality-all patients
	Preoperative chemotherapy for			
	resectable thoracic esophageal			
CD001556	cancer	Preoperative chemotherapy	Surgery alone	Postoperative deaths
	Medical day hospital care for the			
	elderly versus alternative forms		Non-day hospital	
CD001730	of care	Day hospital care	care	Dooth or near outcome
CD001730	of care	, i	care	Death or poor outcome
GD001000	G II . D'	Exercise-based	TT 1	m . 1 12.
CD001800	Coronary Heart Disease	rehabilitation	Usual care	Total mortality
	Treatment of acute bacterial	Third generation	Conventional	
CD001832	meningitis	cephalosporins	therapy	Treatment failure
CD001841	Hypertension	Thiazide	Placebo	Total mortality
CD001041		Tillaziue	Tiacebo	Total mortanty
	Surfactant for meconium			
	aspiration syndrome in full		Placebo or no	
CD002054	term/near term infants	Surfactant therapy	therapy	Mortality
	Prophylactic anastomotic	Prophylactic anastomotic		Clinical anastomotic
			AT 1 '	
CD002100	drainage for colorectal surgery	drainage	No drainage	dehiscence
CD002100			<u> </u>	dehiscence
	Non-ST segment elevation acute	Intravenous IIb/IIIa blockers	Placebo or usual	
CD002100 CD002130	Non-ST segment elevation acute coronary syndromes	Intravenous IIb/IIIa blockers during PCI	<u> </u>	6-month mortality
CD002130	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT)	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative	Placebo or usual care	6-month mortality
	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer	Intravenous IIb/IIIa blockers during PCI	Placebo or usual	
CD002130 CD002142	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT	Placebo or usual care Surgery alone	6-month mortality Mortality
CD002130	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative	Placebo or usual care Surgery alone Vasopressin	6-month mortality
CD002130 CD002142	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin	Placebo or usual care Surgery alone Vasopressin No methadone	6-month mortality Mortality
CD002130 CD002142 CD002147	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal hemorrhage	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT	Placebo or usual care Surgery alone Vasopressin	6-month mortality Mortality Mortality
CD002130 CD002142	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin	Placebo or usual care Surgery alone Vasopressin No methadone	6-month mortality Mortality
CD002130 CD002142 CD002147	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal hemorrhage	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin Methadone maintenance	Placebo or usual care Surgery alone Vasopressin No methadone maintenance	6-month mortality Mortality Mortality
CD002130 CD002142 CD002147	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal hemorrhage Opioid dependence	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin Methadone maintenance	Placebo or usual care Surgery alone Vasopressin No methadone maintenance treatment Placebo or	6-month mortality Mortality Mortality
CD002130 CD002142 CD002147 CD002209	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal hemorrhage Opioid dependence Treatment of severe sepsis and	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin Methadone maintenance treatment	Placebo or usual care Surgery alone Vasopressin No methadone maintenance treatment Placebo or supportive	6-month mortality Mortality Mortality Retention in treatment
CD002130 CD002142 CD002147	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal hemorrhage Opioid dependence Treatment of severe sepsis and septic shock	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin Methadone maintenance treatment Corticosteroids	Placebo or usual care Surgery alone Vasopressin No methadone maintenance treatment Placebo or supportive treatment	6-month mortality Mortality Mortality
CD002130 CD002142 CD002147 CD002209 CD002243	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal hemorrhage Opioid dependence Treatment of severe sepsis and septic shock Kangaroo mother care versus	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin Methadone maintenance treatment Corticosteroids Kangaroo mother care	Placebo or usual care Surgery alone Vasopressin No methadone maintenance treatment Placebo or supportive treatment Conventional	6-month mortality Mortality Mortality Retention in treatment 28-day all-cause mortality
CD002130 CD002142 CD002147 CD002209	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal hemorrhage Opioid dependence Treatment of severe sepsis and septic shock Kangaroo mother care versus conventional neonatal care	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin Methadone maintenance treatment Corticosteroids	Placebo or usual care Surgery alone Vasopressin No methadone maintenance treatment Placebo or supportive treatment	6-month mortality Mortality Mortality Retention in treatment
CD002130 CD002142 CD002147 CD002209 CD002243	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal hemorrhage Opioid dependence Treatment of severe sepsis and septic shock Kangaroo mother care versus conventional neonatal care Prevent ion of thrombosis and	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin Methadone maintenance treatment Corticosteroids Kangaroo mother care	Placebo or usual care Surgery alone Vasopressin No methadone maintenance treatment Placebo or supportive treatment Conventional	6-month mortality Mortality Mortality Retention in treatment 28-day all-cause mortality
CD002130 CD002142 CD002147 CD002209 CD002243	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal hemorrhage Opioid dependence Treatment of severe sepsis and septic shock Kangaroo mother care versus conventional neonatal care Prevent ion of thrombosis and catheter occlusion in neonates	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin Methadone maintenance treatment Corticosteroids Kangaroo mother care	Placebo or usual care Surgery alone Vasopressin No methadone maintenance treatment Placebo or supportive treatment Conventional	6-month mortality Mortality Mortality Retention in treatment 28-day all-cause mortality
CD002130 CD002142 CD002147 CD002209 CD002243	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal hemorrhage Opioid dependence Treatment of severe sepsis and septic shock Kangaroo mother care versus conventional neonatal care Prevent ion of thrombosis and catheter occlusion in neonates with peripherally placed	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin Methadone maintenance treatment Corticosteroids Kangaroo mother care	Placebo or usual care Surgery alone Vasopressin No methadone maintenance treatment Placebo or supportive treatment Conventional	6-month mortality Mortality Mortality Retention in treatment 28-day all-cause mortality
CD002130 CD002142 CD002147 CD002209 CD002243 CD002771	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal hemorrhage Opioid dependence Treatment of severe sepsis and septic shock Kangaroo mother care versus conventional neonatal care Prevent ion of thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin Methadone maintenance treatment Corticosteroids Kangaroo mother care versus	Placebo or usual care Surgery alone Vasopressin No methadone maintenance treatment Placebo or supportive treatment Conventional neonatal care	6-month mortality Mortality Mortality Retention in treatment 28-day all-cause mortality Mortality at latest follow-up
CD002130 CD002142 CD002147 CD002209 CD002243	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal hemorrhage Opioid dependence Treatment of severe sepsis and septic shock Kangaroo mother care versus conventional neonatal care Prevent ion of thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin Methadone maintenance treatment Corticosteroids Kangaroo mother care	Placebo or usual care Surgery alone Vasopressin No methadone maintenance treatment Placebo or supportive treatment Conventional	6-month mortality Mortality Mortality Retention in treatment 28-day all-cause mortality
CD002130 CD002142 CD002147 CD002209 CD002243 CD002771	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal hemorrhage Opioid dependence Treatment of severe sepsis and septic shock Kangaroo mother care versus conventional neonatal care Prevent ion of thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters Acute respiratory distress	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin Methadone maintenance treatment Corticosteroids Kangaroo mother care versus	Placebo or usual care Surgery alone Vasopressin No methadone maintenance treatment Placebo or supportive treatment Conventional neonatal care	6-month mortality Mortality Mortality Retention in treatment 28-day all-cause mortality Mortality at latest follow-up
CD002130 CD002142 CD002147 CD002209 CD002243 CD002771	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal hemorrhage Opioid dependence Treatment of severe sepsis and septic shock Kangaroo mother care versus conventional neonatal care Prevent ion of thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters Acute respiratory distress	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin Methadone maintenance treatment Corticosteroids Kangaroo mother care versus	Placebo or usual care Surgery alone Vasopressin No methadone maintenance treatment Placebo or supportive treatment Conventional neonatal care	6-month mortality Mortality Mortality Retention in treatment 28-day all-cause mortality Mortality at latest follow-up
CD002130 CD002142 CD002147 CD002209 CD002243 CD002771	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal hemorrhage Opioid dependence Treatment of severe sepsis and septic shock Kangaroo mother care versus conventional neonatal care Prevent ion of thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters Acute respiratory distress syndrome and acute lung injury	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin Methadone maintenance treatment Corticosteroids Kangaroo mother care versus Heparin	Placebo or usual care Surgery alone Vasopressin No methadone maintenance treatment Placebo or supportive treatment Conventional neonatal care No heparin	6-month mortality Mortality Mortality Retention in treatment 28-day all-cause mortality Mortality at latest follow-up Catheter occlusion
CD002130 CD002142 CD002147 CD002209 CD002243 CD002771	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal hemorrhage Opioid dependence Treatment of severe sepsis and septic shock Kangaroo mother care versus conventional neonatal care Prevent ion of thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters Acute respiratory distress syndrome and acute lung injury in children and adults	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin Methadone maintenance treatment Corticosteroids Kangaroo mother care versus Heparin Inhaled nitric oxide	Placebo or usual care Surgery alone Vasopressin No methadone maintenance treatment Placebo or supportive treatment Conventional neonatal care No heparin Placebo or no intervention	6-month mortality Mortality Mortality Retention in treatment 28-day all-cause mortality Mortality at latest follow-up
CD002130 CD002142 CD002147 CD002209 CD002243 CD002771 CD002772 CD002787	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal hemorrhage Opioid dependence Treatment of severe sepsis and septic shock Kangaroo mother care versus conventional neonatal care Prevent ion of thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters Acute respiratory distress syndrome and acute lung injury in children and adults Blood-pressure lowing in acute	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin Methadone maintenance treatment Corticosteroids Kangaroo mother care versus Heparin Inhaled nitric oxide Blood pressure lowering	Placebo or usual care Surgery alone Vasopressin No methadone maintenance treatment Placebo or supportive treatment Conventional neonatal care No heparin Placebo or no intervention Placebo or no	6-month mortality Mortality Mortality Retention in treatment 28-day all-cause mortality Mortality at latest follow-up Catheter occlusion Longest follow up mortality
CD002130 CD002142 CD002147 CD002209 CD002243 CD002771	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal hemorrhage Opioid dependence Treatment of severe sepsis and septic shock Kangaroo mother care versus conventional neonatal care Prevent ion of thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters Acute respiratory distress syndrome and acute lung injury in children and adults	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin Methadone maintenance treatment Corticosteroids Kangaroo mother care versus Heparin Inhaled nitric oxide	Placebo or usual care Surgery alone Vasopressin No methadone maintenance treatment Placebo or supportive treatment Conventional neonatal care No heparin Placebo or no intervention	6-month mortality Mortality Mortality Retention in treatment 28-day all-cause mortality Mortality at latest follow-up Catheter occlusion Longest follow up mortality Death at end of trial
CD002130 CD002142 CD002147 CD002209 CD002243 CD002771 CD002772 CD002787 CD002839	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal hemorrhage Opioid dependence Treatment of severe sepsis and septic shock Kangaroo mother care versus conventional neonatal care Prevent ion of thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters Acute respiratory distress syndrome and acute lung injury in children and adults Blood-pressure lowing in acute stroke	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin Methadone maintenance treatment Corticosteroids Kangaroo mother care versus Heparin Inhaled nitric oxide Blood pressure lowering therapy	Placebo or usual care Surgery alone Vasopressin No methadone maintenance treatment Placebo or supportive treatment Conventional neonatal care No heparin Placebo or no intervention Placebo or no intervention	6-month mortality Mortality Mortality Retention in treatment 28-day all-cause mortality Mortality at latest follow-up Catheter occlusion Longest follow up mortality Death at end of trial Rotavirus diarrhoea:
CD002130 CD002142 CD002147 CD002209 CD002243 CD002771 CD002772 CD002787	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal hemorrhage Opioid dependence Treatment of severe sepsis and septic shock Kangaroo mother care versus conventional neonatal care Prevent ion of thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters Acute respiratory distress syndrome and acute lung injury in children and adults Blood-pressure lowing in acute stroke	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin Methadone maintenance treatment Corticosteroids Kangaroo mother care versus Heparin Inhaled nitric oxide Blood pressure lowering	Placebo or usual care Surgery alone Vasopressin No methadone maintenance treatment Placebo or supportive treatment Conventional neonatal care No heparin Placebo or no intervention Placebo or no intervention	6-month mortality Mortality Mortality Retention in treatment 28-day all-cause mortality Mortality at latest follow-up Catheter occlusion Longest follow up mortality Death at end of trial
CD002130 CD002142 CD002147 CD002209 CD002243 CD002771 CD002772 CD002787 CD002839 CD002848	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal hemorrhage Opioid dependence Treatment of severe sepsis and septic shock Kangaroo mother care versus conventional neonatal care Prevent ion of thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters Acute respiratory distress syndrome and acute lung injury in children and adults Blood-pressure lowing in acute stroke Diarrhoea prevention Mild to moderate hypertension	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin Methadone maintenance treatment Corticosteroids Kangaroo mother care versus Heparin Inhaled nitric oxide Blood pressure lowering therapy Rotavirus vaccine	Placebo or usual care Surgery alone Vasopressin No methadone maintenance treatment Placebo or supportive treatment Conventional neonatal care No heparin Placebo or no intervention Placebo or no intervention Placebo Placebo or no	6-month mortality Mortality Retention in treatment 28-day all-cause mortality Mortality at latest follow-up Catheter occlusion Longest follow up mortality Death at end of trial Rotavirus diarrhoea: episodes
CD002130 CD002142 CD002147 CD002209 CD002243 CD002771 CD002772 CD002787 CD002839	Non-ST segment elevation acute coronary syndromes Postoperative radiotherapy (RT) for non-small cell lung cancer Acute esophageal variceal hemorrhage Opioid dependence Treatment of severe sepsis and septic shock Kangaroo mother care versus conventional neonatal care Prevent ion of thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters Acute respiratory distress syndrome and acute lung injury in children and adults Blood-pressure lowing in acute stroke	Intravenous IIb/IIIa blockers during PCI Surgery plus post-operative RT Terlipressin Methadone maintenance treatment Corticosteroids Kangaroo mother care versus Heparin Inhaled nitric oxide Blood pressure lowering therapy	Placebo or usual care Surgery alone Vasopressin No methadone maintenance treatment Placebo or supportive treatment Conventional neonatal care No heparin Placebo or no intervention Placebo or no intervention Placebo	6-month mortality Mortality Mortality Retention in treatment 28-day all-cause mortality Mortality at latest follow-up Catheter occlusion Longest follow up mortality Death at end of trial Rotavirus diarrhoea:

CD003241 Jupus nephritis CD003041 Part disease CD003040 Prevention of Coronary CD003288 Prevention of invasive fungal infections CD003288 Prevention of invasive fungal infections CD003288 Prevention of invasive fungal infections CD003280 Prevention of invasive fungal infections CD003481 Infants CD003481 Infants CD003482 Support systems of part makes with cancer receiving restment of parent ductus arerions in prevention of oral candidatists for prevention or foral candidatists for prevention or prevention or prevention general properties and propert		Cirrhotic patients with upper GI	I		-
Lapus nephritis Sunoking essation for the security of the properties of the prop	CD002907		Antibiotics		Bacterial infections
Exercised Security Exercis	02002907	- orecoming			
Secondary prevention of coronary	CD002922	Lupus nephritis		Steroids alone	
Commonstration Comm		Smoking cessation for the			
CD003286 Elderly people at risk from preventing nenotal infections CSF versus Control					
CD003606 CD003606 CD003607	CD003041		Ceased smoking	Continued smoking	
Elderly people at risk from prevention of invasive fungal infection in very low birth weight infacts in increase infection in very low birth weight infacts in fairs. CD03488 infants CD03481 infants CD03481 infants CD03481 infants CD03482 infants Meconium aspiration syndrome in newborn infants Support systems versus standard medical therapy Prevention of oral candidusis for patients with cancer receiving treatment CD036282 infants CD036287 in newborn infants Support systems versus standard medical therapy Prevention of oral candidusis for patients with cancer receiving treatment CD03629 in the control of oral candidusis for patients with cancer receiving treatment CD03629 in the control of oral candidusis for patients with cancer receiving treatment CD03629 in the control of oral candidusis for patients with cancer receiving treatment CD03629 in the control of oral candidusis for patients with cancer receiving treatment CD03629 in the control or oral candidusis for patients with cancer receiving treatment CD03629 in the control oral candidusis for patients with cancer receiving treatment CD03629 in the control oral candidusis for patients with cancer receiving the patients with cancer receiving the patients with cancer patients CD03629 in the control oral candidusis for patients with cancer patients CD03629 in the control oral candidusis for patients with cancer patients CD03629 in the control oral candidusis for patients with cancer patients CD03629 in the control oral cancer patients Vitamin E supplementation in pregnancy Vitamin E supplementation in pregnancy Vitamin C supplementation in pregnancy Vitamin C supplementation in pregnancy CD03629 in the control oral cancer patients CD03629 in the control oral cancer patients following patients following chemotherapy in the cancer patients following chemotherapy in the control oral cancer in a for but					_
Prevention of invasive fungal infection in very low birth weight infants Draw of the process of preventions of invasive fungal infection in very low birth weight infants Draw of the prevention of invasive fungal infants Draw of the prevention of invasive fungal infants Draw of the prevention of invasive fungal infants Draw of the prevention of the treatment of patent ductus arteriosus in preterm and/or low birth weight infants Draw of the prevention of patent ductus arteriosus in preterm and/or low birth weight infants Draw of the prevention of patent ductus arteriosus in preterm and/or low birth weight infants Draw of the prevention of patent ductus arteriosus in preterm and/or low birth weight infants Draw of the prevention of machinary prevent mortality and northistip in very low birth weight infants Draw of the prevention of patent ductus arteriosus in preterm and/or low birth weight infants Draw of the prevention of patent ductus arteriosus in preterm and/or low birth weight infants Draw of the prevention of machinary prevent mortality in the properties for treatment Draw of the prevention of machinary prevent mortality in the properties for treatment Draw of the prevention of patent ductus arteriosus in prevent mortality in the properties of the prevention of machinary prevent mortality prevention of patent ductus arteriosus in prevent mortality in the prevention of patent ductus arteriosus in prevention of mortality in the prevention of patent ductus arteriosus in prevention of mortality in the prevention of mortality in the prevention of patent ductus arteriosus in prevention of mortality in prevention of mortality in prevention of mortality in prevention of mortality and mortality in prevention of mortality in prevention of mortality in prevention of mortality in prevention of mortality and mortality in prevention of mortality in prevention	CD003066		CSF versus	Control	days
Prevention of invasive fungal infaction in very low birth weight infants Duprofen for the treatment of patent dactus arteriosus in preterm and/or low birth weight infants Duprofen for the treatment of patent dactus arteriosus in preterm and/or low birth weight infants Duprofen for the treatment of patent dactus arteriosus in preterm and/or low birth weight infants Duprofen Duprofen for the treatment of patent dactus arteriosus in a dactus arteriosus in preterm or or preturn or drop birth weight infants Duprofen Dup	CD002200			D. d	3.6 . 1.
infection in very low birth weight infants Duprofen for the treatment of patent ductors arterious in preterm and/or low birth weight infants Duprofen for the treatment of patent ductors arterious in preterm and/or low birth weight infants Duprofen Duprofen	CD003288		Oral protein and energy	Routine care	Mortality
Depot			Oral/tonical non-absorbed		Incidence of invasive fungal
Disprofer for the treatment of patent ductus arrefroisus in preterm and/or low birth weight infants Disprofer	CD003478			Placebo or nothing	
patent ductus arteriosus in preterm and/or low birth weight infants Duprofen Dupro	CD003470		antifungui propriytuxis	Traceoo or nothing	meetion
Dretern and/or low birth weight infants Duprofen Drugs absorbed from GI reatment Drugs absorbed from					
CD003481 Infants					
Seroid Placebo discharge Support systems versus standard medical therapy Prevention of oral candidiasis for prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants The prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants The prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants The prophylactic systemic antifungal agent to prevent mortality and morbidity in very low birth weight infants The prophylactic systemic antifungal agent to prevent mortality and morbidity in very low birth weight infants The prophylactic systemic antifungal agent to prevention of prophylactic systemic antifungal agent to prevention of corticosteroids for women at risk of preterm birth for improving conticosteroids for women at risk of preterm birth for improving conticosteroids for women at risk of preterm birth for improving conticosteroids for women at risk of preterm birth for improving conticosteroids of corticosteroids or	CD003481	infants	Ibuprofen	Indomethacin	Failure to close a PDA
Support systems versus standard medical therapy Support systems					
Prevention of oral candidiasis for patients with cancer receiving treatment Drugs absorbed from GI treatment Placebo or no treatment Drugs absorbed from GI treatment Placebo or no treatment Drugs absorbed from GI treatment Placebo or no treatment Drugs absorbed from GI treatment	CD003485		Steroid		discharge)
Prevention of oral candidiasis for putients with cancer receiving treatment Prophylactic systemic antifungal agents to prevent mortality and morbidity and	an ac				
Drugs absorbed from GI Placebo or no treatment Tract treatme	CD003628	medical therapy	Support systems	therapy	Mortality
Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants Systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants Systemic antifungal agent Placebo or no treatment Invasive fungal infection Placebo or no treatment Placebo or no treat			Drugg absorbed from CI	Dlacaba ann-	
Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants Systemic antifungal agent to prevent mortality and morbidity in very low birth weight infants Placebo or no Invasive fungal infection Invasive funcal interaction Invasive function In	CD002907				Oral candidiasis
agents to prevent mortality and morbidity in very low birth weight infants CD003850 Interleukin 2 receptor antagonists CD003897 for kidney transplant recipients CD003935 CD0	CD003807		tract	treatment	Oral calididiasis
morbidity in very low birth CD003850 weight infants Systemic antifungal agent Placebo or no Invasive fungal infection Placebo or no Graft loss or death with functioning allograft					
CD003850 weight infants Systemic antifungal agent treatment Invasive fungal infection CD003897 Interleukin 2 receptor antagonists Interleukin 2 reactions of chroine Invasive fungal infection Interleukin 2 Interleukin 2 Interleukin 2 Interleukin 3 Interleukin 4 Interleuk				Placebo or no	
Interleukin 2 receptor antagonists CD00397 for kidney transplant recipients Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes CD003935 Thymic peptides for treatment Synthetic thymic peptides CD003935 Thymic peptides for treatment Synthetic thymic peptides CD003935 Thymic peptides for treatment Synthetic thymic peptides Placebo or no treatment CD004069 Vitamin E supplementation in pregnancy Vitamin C supplementation in pregnancy Vitamin C supplementation in pregnancy Vitamin C Placebo or no treatment Placebo or no treatment Overall survival Tracheal intubation CD004072 Prevention gastrointestinal cancers NPPV + Usual medical care Usual medical care Tracheal intubation Occurrence of gastrointestinal cancers in trials with a low or high risk of bias Duprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants Duprofen Antioxidants for preventing precalampsia Any antioxidants Placebo or no presence of PDA on 3rd day of life (72 hours of age) Prophylaxis for bacterial infants Ethamsylate Placebo or no intervention Precalampsia Precalampsia Prophylaxis for bacterial infants Ethamsylate Placebo or no intervention Placebo or no intervention All-cause mortality Placebo or no intervention All-cause mortality Placebo or no intervention All-cause mortality Placebo or no intervention Placebo or no intervention All-cause mortality Placebo or no intervention Placebo or no intervention All-cause mortality Placebo or no intervention Placebo or no intervention Placebo or no intervention All-cause mortality Placebo or no intervention Placebo or no intervention Placebo or no intervention Placebo or no intervention All-cause mortality Placebo or no intervention	CD003850		Systemic antifungal agent		Invasive fungal infection
Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes or corticosteroids for treatment of thy pregnancy or pregnancy or pregnancy or vitamin E supplementation in treatment or supplementation in pregnancy or vitamin E supplementation in pregnancy or vitamin E supplementation in treatment or supplementation in treatment or supplementation or supplementation in treatment or supplementation or supplementation in treatment or supplementation in treatm				Placebo or no	
corticosteroids for women at risk of preterm birth for improving neonatal health outcomes neonatal mortality Placebo or no treatment of treatment of Placebo or no treatment of Placebo or no treatment of Placebo or no treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease NPPV +Usual medical care Usual medical care Tracheal intubation of patent ductus arterious in preterm and/or low birth weight infants Antioxidants Placebo or no patent ductus arterious in preterm and/or low birth weight infants Placebo and mortality in preterm and/or low birth weight infants Placebo intervention and mortality in preterm and/or low birth weight infants Prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy Antenatal corticosteroids corticosteroids corticosteroids corticosteroids corticosteroids corticosteroids corticosteroids princetom and of low birth weight infections in afebrile neutropenic patients following chemotherapy Antenatal corticosteroids for corticosteroids or corticosteroids or treatment Placebo or no intervention in treatment Placebo or no intervention intervention intervention All-cause mortality discharge Placebo or no intervention intervention intervention intervention intervention All-cause mortality discharge Repairatory distress Placebo or no intervention	CD003897	for kidney transplant recipients	IL2 receptor antagonists	treatment	functioning allograft
CD003935					
CD003935 neonatal health outcomes Corticosteroids Corticosteroids Fetal and neonetal mortality					
Thymic peptides for treatment of cancer patients Vitamin E supplementation in pregnancy Vitamin C supplementation in pregnancy Vitamin E supplementation in predementation in predementation in predementation in supplementation in predement case or no intervention in pregnancy supplementation in predement case or no intervention in predementation in p	an				
CD004099 Cancer patients	CD003935		corticosteroids		Fetal and neonetal mortality
CD004069 Vitamin E supplementation in pregnancy Vitamin E Placebo or no treatment Clinical pre-eclampsia	CD002002		Crimthatia thromia mantidas		Overall survival
CD004069 pregnancy Vitamin E treatment Clinical pre-eclampsia	CD003993		Synthetic thymic peptides		Overali survivai
Vitamin C supplementation in pregnancy Non-invasive positive pressure ventilation (NPPV) for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease CD004104 Drevention gastrointestinal cancers Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants CD004213 Ethamsylate for the prevention of morbidity and mortality in preterm or very low birth weight infants CD004343 Prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy Antenatal corticosteroids for accelerating fetal lung maturation Vitamin C Vitamin C Vitamin C Placebo or no treatment gestation) Prevention treatment Prevention (A) Placebo or no intervention of patent ductus arteriosus in preterm and/or low birth weight infants Any antioxidants Placebo or no intervention Prevention day of life (72 hours of age) Pre-eclampsia Any antioxidants Placebo or no intervention Mortality to hospital discharge Placebo or no intervention All-cause mortality Alterated corticosteroids for accelerating fetal lung maturation Placebo or no Respiratory distress	CD004069	= =	Vitamin F		Clinical pre-eclampsia
CD004104 Pregnancy Vitamin C treatment gestation	CD00400)	Vitamin C supplementation in	Vitaliiii E		
Non-invasive positive pressure ventilation (NPPV) for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease CD004104 NPPV +Usual medical care Usual medical care Usual medical care Tracheal intubation Occurrence of gastrointestinal cancers in trials with a low or high risk of bias CD004183 cancers Antioxidants Placebo of bias Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants CD004213 Infants Ibuprofen intervention of morbidity and mortality in preterm or very low birth weight infants Ethamsylate for the prevention of morbidity and mortality in preterm or very low birth weight infants Ethamsylate For phylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy Antenatal corticosteroids for accelerating fetal lung maturation Antenatal corticosteroids for accelerating fetal lung maturation PAUS Antenatal corticosteroids for accelerating fetal lung maturation PAUS Antenatal corticosteroids for accelerating fetal lung maturation NPPV +Usual medical care Usual medical care Usual medical care Tracheal intubation Doccurrence of gastrointestinal enteroal intrials with a low or high risk of bias Placebo or no intervention Mortality to hospital discharge Placebo or no intervention All-cause mortality	CD004072	1.1	Vitamin C		,
of respiratory failure due to exacerbations of chronic obstructive pulmonary disease CD004104 NPPV +Usual medical care Vusual medical care Usual medical care Tracheal intubation Occurrence of gastrointestinal trials with a low or high risk of bias CD004183 CD004183 CD004184 Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants Ibuprofen Antioxidants Ibuprofen Antioxidants for preventing precelampsia Ethamsylate for the prevention of morbidity and mortality in preterm or very low birth weight infants Ethamsylate for bacterial infections in afebrile neutropenic patients following chemotherapy Antenatal corticosteroids for accelerating fetal lung maturation Antenatal corticosteroids for accelerating fetal lung maturation Antenatal corticosteroids for accelerating fetal lung maturation NPPV +Usual medical care Usual medical care Tracheal intubation Occurrence of gastrointestinal cancers in trials with a low or high risk of trials with a low or high risk of pastrointestinal cancers in trials with a low or high risk of pastrointestinal cancers in trials with a low or high risk of bastrointestinal cancers in trials with a low or high risk of bastrointestinal cancers in trials with a low or high risk of bastrointestinal cancers in trials with a low or high risk of bastrointestinal cancers in trials with a low or high risk of bastrointestinal cancers in trials with a low or high risk of bastrointestinal cancers in trials with a low or high risk of bastrointestinal cancers in trials with a low or high risk of bastrointestinal cancers in trials with a low or high risk of bastrointestinal cancers in trials with a low or high risk of bastrointestinal cancers in trials with a low or high risk of bastrointestinal cancers in trials with a low or high risk of bastrointestinal cancers in trials with a low or high risk of bastrointestinal cancers in trials with a low or high risk of bastrointestinal cancers in trials with a low or high risk of bastrointestinal p					,
exacerbations of chronic obstructive pulmonary disease CD004104 Prevention gastrointestinal cancers Prevention gastrointestinal cancers Antioxidants Placebo Placebo Presence of PDA on 3rd day of life (72 hours of age) CD004213 Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants Ibuprofen Ibuprofen Ibuprofen Antioxidants for preventing prechampsia Any antioxidants Placebo Pre-eclampsia CD004227 Ethamsylate for the prevention of morbidity and mortality in preterm or very low birth weight infants Ethamsylate Placebo Placebo Pre-eclampsia CD004343 Placebo Placebo Placebo Placebo Placebo Pre-eclampsia CD004386 Prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy Quinolone Placebo All-cause mortality Antenatal corticosteroids for accelerating fetal lung maturation Placebo Placebo Respiratory distress		ventilation (NPPV) for treatment			
CD004104 obstructive pulmonary disease NPPV +Usual medical care Usual medical care Tracheal intubation Prevention gastrointestinal CD004183 cancers Antioxidants Placebo of bias CD004184 Disprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants Ibuprofen CD004213 infants Ibuprofen CD004227 eclampsia Any antioxidants Placebo Pre-eclampsia Ethamsylate for the prevention of morbidity and mortality in preterm or very low birth weight infants CD004343 infants Ethamsylate Prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy Antenatal corticosteroids for accelerating fetal lung maturation Placebo or no intervention Placebo or no intervention Placebo or no intervention All-cause mortality Placebo or no Respiratory distress		1 1			
Prevention gastrointestinal CD004183 cancers Antioxidants Placebo Presence of gastrointestinal cancers in trials with a low or high risk of bias Dour of bias Deprote for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants Dour of bias Deprote for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants Dour of bias Deprote for the prevention of morbidity and mortality in preterm or very low birth weight infants Dour of bias Deprote for the prevention of morbidity and mortality in preterm or very low birth weight infants Dour of bias Deprote for for bias					
Prevention gastrointestinal cancers in trials with a low or high risk of bias CD004183 Cancers CD004213 CD004213 CD004213 CD004227 CD004227	CD004104	obstructive pulmonary disease	NPPV +Usual medical care	Usual medical care	
Prevention gastrointestinal cancers Antioxidants Placebo Placebo Prevention gastrointestinal cancers Antioxidants Placebo Placebo Presence of PDA on 3rd Buprofen intervention Presence of PDA on 3rd Buprofen Ibuprofen Ibuprofen Ibuprofen Ibuprofen Antioxidants for preventing preclampsia Ethamsylate for the prevention of morbidity and mortality in preterm or very low birth weight infants Prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy Antenatal corticosteroids for accelerating fetal lung maturation Antioxidants Placebo Placebo Placebo Placebo Antioxidants Placebo Placebo Any antioxidants Placebo Pre-eclampsia Mortality to hospital discharge Placebo or no intervention All-cause mortality Placebo or no Respiratory distress					
CD004183 cancers Antioxidants Placebo of bias Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants Ibuprofen		Prevention gastrointestinal			
Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants Ibuprofen Placebo or no intervention Presence of PDA on 3rd	CD004183		Antioxidants	Placebo	
patent ductus arteriosus in preterm and/or low birth weight infants CD004213 Ibuprofen Antioxidants for preventing precelampsia Ethamsylate for the prevention of morbidity and mortality in preterm or very low birth weight infants Ethamsylate for bacterial infections in afebrile neutropenic CD004386 CD004386 Prophylaxis for bacterials accelerating fetal lung maturation Placebo or no intervention Placebo or no intervention Placebo or no intervention Presence of PDA on 3rd day of life (72 hours of age) Pre-eclampsia Pre-eclampsia Pre-eclampsia Placebo or no discharge Placebo or no intervention All-cause mortality Placebo or no Respiratory distress	22007103			- 100000	
preterm and/or low birth weight infants CD004213 infants Ibuprofen Ibuprofen Antioxidants for preventing precelampsia Ethamsylate for the prevention of morbidity and mortality in preterm or very low birth weight infants Ethamsylate for bacterial infections in afebrile neutropenic CD004386 CD004386 Prophylaxis for bacterials infants Any antioxidants Placebo Pre-eclampsia Placebo Mortality to hospital discharge Ethamsylate Placebo or no intervention Placebo or no intervention All-cause mortality Antenatal corticosteroids for accelerating fetal lung maturation Placebo or no Respiratory distress					
Antioxidants for preventing pre- eclampsia Any antioxidants Placebo Pre-eclampsia Ethamsylate for the prevention of morbidity and mortality in preterm or very low birth weight infants Ethamsylate Placebo discharge Prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy Quinolone Quinolone intervention All-cause mortality Antenatal corticosteroids for accelerating fetal lung maturation Placebo or no Respiratory distress					
CD004227 eclampsia Any antioxidants Placebo Pre-eclampsia Ethamsylate for the prevention of morbidity and mortality in preterm or very low birth weight infants Ethamsylate Placebo Mortality to hospital discharge Prophylaxis for bacterial infections in afebrile neutropenic CD004386 patients following chemotherapy Quinolone intervention All-cause mortality Antenatal corticosteroids for accelerating fetal lung maturation Placebo or no Respiratory distress	CD004213		Ibuprofen	intervention	day of life (72 hours of age)
Ethamsylate for the prevention of morbidity and mortality in preterm or very low birth weight infants CD004343 infants Ethamsylate Prophylaxis for bacterial infections in afebrile neutropenic CD004386 patients following chemotherapy Antenatal corticosteroids for accelerating fetal lung maturation Ethamsylate Placebo Placebo or no intervention All-cause mortality Placebo or no Respiratory distress					
morbidity and mortality in preterm or very low birth weight infants CD004343 Prophylaxis for bacterial infections in afebrile neutropenic CD004386 Patients following chemotherapy Quinolone Antenatal corticosteroids for accelerating fetal lung maturation Mortality to hospital discharge Placebo or no intervention All-cause mortality Placebo or no Respiratory distress	CD004227	eclampsia	Any antioxidants	Placebo	Pre-eclampsia
preterm or very low birth weight infants Ethamsylate Placebo Prophylaxis for bacterial infections in afebrile neutropenic CD004386 Antenatal corticosteroids for accelerating fetal lung maturation Placebo or no Placebo or no Placebo or no Placebo or no Respiratory distress					
CD004343 infants Ethamsylate Placebo discharge Prophylaxis for bacterial infections in afebrile neutropenic CD004386 patients following chemotherapy Quinolone intervention All-cause mortality Antenatal corticosteroids for accelerating fetal lung maturation Placebo or no Respiratory distress	1				Mortality to bosnit-1
Prophylaxis for bacterial infections in afebrile neutropenic CD004386 patients following chemotherapy Quinolone intervention All-cause mortality Antenatal corticosteroids for accelerating fetal lung maturation Placebo or no Respiratory distress	CD004343		Ethamsylate	Placebo	
infections in afebrile neutropenic Placebo or no patients following chemotherapy Quinolone intervention All-cause mortality Antenatal corticosteroids for accelerating fetal lung maturation Placebo or no Respiratory distress	CD00+343		- Litanis yran	110000	discharge
CD004386 patients following chemotherapy Quinolone intervention All-cause mortality Antenatal corticosteroids for accelerating fetal lung maturation Placebo or no Respiratory distress				Placebo or no	
Antenatal corticosteroids for accelerating fetal lung maturation Placebo or no Respiratory distress	CD004386		Quinolone		All-cause mortality
CD004454 for women at risk of preterm birth Corticosteroids intervention syndrome					
	CD004454	for women at risk of preterm birth	Corticosteroids	intervention	syndrome

	Primary intracerebral		Placebo or standard	Death at the end of follow
CD004583	haemorrhage	Glucocorticoid treatment	strategy	up
	Antiplatelet agents for preventing			
	pre-eclampsia and its		Placebo or no	
CD004659	complications	Antiplatelet agents	intervention	Proteinuric pre-eclampsia
	Prophylactic oral betamimetics			B
GD004722	for reducing preterm birth in		DI 1	Preterm birth (less than 37
CD004733	women with a twin pregnancy	Oral betamimetic	Placebo	weeks' gestation)
	Primary prevention of			T '1 C' '
CD004772	cryptococcal disease in adults	A CC 1	DI I	Incidence of invasive
CD004773	with HIV	Antifungals	Placebo	cryptococcal disease
GD004776	Treatment for anemia in people	E ' I HAADE	Placebo plus	D 4
CD004776	with AIDS.	Epoetin plus HAART	HAART	Death
GD 00 4770	Laparoscopic repair for			Number of septic
CD004778	perforated peptic ulcer disease	Laparoscopic surgery	Open surgery	abdominal complications
GD004707	Unresectable hepatocellular	TACE TAE	Placebo or no	A 11
CD004787	carcinoma	TACE or TAE	intervention	All-cause mortality
	Antibiotic prophylaxis for			
İ	spontaneous bacterial peritonitis		DI 1	
GD004704	in cirrhotic patients with ascites,	A 1 1 .	Placebo or no	34 (1)
CD004791	without gastro-intestinal bleeding	Antibiotic prophylaxis	treatment	Mortality
	Early erythropoietin (EPO) for			
	preventing red blood cell			
GD004043	transfusion in preterm and/or low		Placebo or no	Use of one or more red
CD004863	birth weight infants	Early erythropoietin	treatment	blood cell transfusions
	Late initiation of EPO (8-28			
	days) vs placebo or no			
	intervention for preventing red			
GT 00 10 10	blood cell transfusion in preterm		Placebo or no	Use of one or more red
CD004868	and/or low birth weight infants	Late erythropoietin	treatment	blood cell transfusions
apos in a	Prevention meningitis in patients		Placebo or no	
CD004884	with basilar skull fractures	Antibiotic prophylaxis	treatment	Frequency of meningitis
	Multiple-micronutrient		No supplements,	
	supplementation for women		placebo or less than	
CD004905	during pregnancy	Multiple micronutrients	two micronutrients	Perinatal mortality
	Preventing fungal infections in			
	non-neutropenic critically ill		Placebo/no	
CD004920	patients	Systemic antifungal	antifungal	Mortality
	Improving birth outcomes for		Expectant	
CD004945	women at or beyond term	Labour induction	management	Perinatal death
	Preventing vaccine-type invasive			
	pneumococcal disease and X-ray			
	defined pneumonia in children		Placebo or no	
CD004977	less than two years of age	Pneumococcal vaccine	intervention	Vaccine serotypes
	Terlipressin for hepatorenal			
CD005162	syndrome	Octreotide or terlipressin	Placebo	Mortality
				Overall survival
CD005413	Metastatic malignant melanoma	Chemoimmunotherapy	Chemotherapy	Treatment-related mortality
	Proton pump inhibitor treatment			
	prior to endoscopic diagnosis in		Placebo or no	Mortality - 30 days or at
CD005415	upper gastrointestinal bleeding	Proton pump inhibitors	intervention	point closest to 30 days
		Pre-operative biliary		
CD005444	Obstructive jaundice	drainage	Direct surgery	Mortality
·	Prevention of necrotizing		Placebo or no	
CD005496	enterocolitis in preterm infants.	Probiotics	intervention	Sepsis
	ERCP in patients with			
	pancreaticobiliary malignancy,			
CD006001	prior to surgery	With stenting	Without stenting	Overall mortality
				Caesarean section for
	Electronic fetal monitoring for	Continuous	Intermittent	abnormal FHR pattern
CD006066	fetal assessment during labour	cardiotocography	auscultation	and/or acidosis
	Routine abdominal drainage for	<u> </u>		Intra-abdominal collection
CD006232	uncomplicated liver resection	Drain	No drain	requiring drain insertion
	Oral cavity and oropharyngeal	Altered fractionation	Conventional	1
CD006387	cancer	radiotherapy	radiotherapy	Total mortality
000001				

	Immunoglobulin prophylaxis in			
	hematological malignancies and hematopoietic stem cell	Polyvalent immunoglobulins or	D11/	
CD006501	transplantation	hyperimmune CMV-IVIG	Placebo / no intervention	All-cause Mortality
CD000301	Stem cell treatment for acute	Bone marrow-derived stem	No bone marrow-	7 th-cause Wortanty
CD006536	myocardial infarction	cells	derived stem cells	Mortality
			Placebo or no	All-cause mortality at 10
		Beta-blockers	treatment	days
	Early treatment with anti-		Placebo or no	All-cause mortality at 10
	hypertensive drugs in patients	Calcium-channel blockers	treatment	days
	with an acute cardiovascular		Placebo or no	All-cause mortality at 10
CD006743	event	Nitrates	treatment	days
				Combined outcome of
	Stating for south coronery			nonfatal myocardial infarction, nonfatal stroke,
CD006870	Statins for acute coronary syndrome	Statins	Placebo/ usual care	and total number of deaths
CD000870	Infectious complications in	Statins	Tiaccoo/ usuar care	and total number of deaths
	haemodialysis patients with	Topical antimicrobial	No ointment/	Catheter-related
CD006894	central venous catheters	ointment	placebo	bacteraemia
		Selective or concealed	Routine or revealed	
	Ultrasound for fetal assessment in	ultrasound in early	ultrasound in early	
CD007058	early pregnancy	pregnancy	pregnancy	Perinatal death (all babies)
	Multidisciplinary rehabilitation			
GD007125	for older people with hip	Multidisciplinary inpatient	T. 1	Mortality (end of scheduled
CD007125	fractures	rehabilitation	Usual care	follow-up)
	Antioxidant supplements for prevention of mortality in healthy			
	participants and patients with		Placebo or no	
CD007176	various diseases	Antioxidants	intervention	Mortality
CDOOTITO	Structured telephone support or	TittloAldults	intervention	Wortunty
	telemonitoring programmes for	Structured telephone		
CD007228	patients with chronic heart failure	support	Usual care	All-cause mortality
	Pentoxifylline for alcoholic		Placebo or standard	
CD007339	hepatitis	Pentoxifylline	treatment	All-cause mortality
	Intra-aortic balloon pump		NT 1	
	counterpulsation for myocardial infarction complicated by	Intro contic halloon numn	No intra-aortic	
CD007398	cardiogenic shock	Intra-aortic balloon pump counterpulsation	balloon pump counterpulsation	All-cause mortality
CD007378	Vascular occlusion for elective	Counterpulsation	No vascular	An-eause mortanty
CD007530	liver resections	Vascular occlusion	occlusion	Number needing transfusion
	Rehabilitation interventions for			
	improving physical and			Poor outcome: dead or
	psychosocial functioning after hip			readmitted or failed to
CD007624	fracture in older people	Specialist nurse led care	Usual care	return home
GD007740	Antioxidant supplements for liver		Placebo or no	A 11
CD007749	diseases Community based intervention	Antioxidants	intervention	All-cause mortality
	Community-based intervention packages for reducing maternal			
	and neonatal morbidity and			
	mortality and improving neonatal	Community-based		
CD007754	outcomes.	intervention	Standard care	Neonatal mortality
	Statins for people with chronic			
	kidney disease not requiring		Placebo or no	
CD007784	dialysis	Statins	treatment	All-cause mortality
	Monitoring haemotherapy versus			
CD007071	usual care in patients with	Thrombelastography or	Routine coagulation	I
CD007871	massive transfusion	thromboelastometry	tests Standard treatment	Longest follow-up mortality
	Prophylactic phototherapy for		or no use of	
	preventing jaundice in preterm or		prophylactic	
CD007966	low birth weight infants	Prophylactic phototherapy	phototherapy	Exchange transfusion
	Secondary prevention of vascular	1 J	1	<i>5</i>
	events after stroke of arterial			Stroke, MI or vascular
CD008076	origin	Cilostazol in patients	Aspirin	death during follow-up
	Prevention and treatment of		Placebo or no	All-cause mortality at the
CD008238	infectious complications in	Colony-stimulating factors	treatment	end of follow up

	patients with acute myelogenous leukemia			
	Somatostatin analogues for			
CD008370	pancreatic surgery	Somatostatin analogues	No intervention	Perioperative mortality
				Death or severe disability
				(GOS 1 to 3) at the end of
CD008409	Brain injury	Progesterone	Placebo	the follow-up period
				Rotavirus diarrhoea of any
CD008521	Rotavirus diarrhoea	Rotarix	Placebo	severity
	Probiotics for patients with		Placebo or no	No recovery from hepatic
CD008716	hepatic encephalopathy	Probiotic	intervention	encephalopathy

BCG: Bacille Galmett-Guerin vaccine; CDSR: Cochrane Database of Systematic


Reviews; GCS: Glasgow Coma Scale; HIV: human immunodeficiency; IVIG:

intravenous immunoglobulin; MI: myocardial infarction; TB: tuberculosis


Fig A3. Primary binary outcomes with significant differences in treatments effects between less developed countries and more developed countries (Panels **A-N**). (A) Bacterial infections with antibiotic prophylaxis in cirrhotic patients with upper GI bleeding. (B) Prevention of pre-eclampsia antioxidants. (C) Prevention of proteinuric pre-eclampsia with antiplatelet agents. (D) Development of active tuberculosis with isoniazid in non-HIV infected persons. (E) Invasive fungal infections with prophylactic usage of fluconazole in very low birth weight infants. (F) Cardiovascular events with lipid-lowering regimens for peripheral arterial disease. (G) All-cause pneumonia with vaccination for preventing pneumococcal infection in adults. (H) Prevention of clinical pre-eclampsia with vitamin E supplementation in pregnancy. (I) Prevention of GI cancers with antioxidants. (J) Need for caesarian section with beta-blockers for hypertension during pregnancy. (K) No recovery from hepatic encephalopathy with probiotics. (L) Sepsis in pre-term and/or low-birth weight infants with intravenous immunoglobulin. (M) Pre-term birth with reduced number of antenatal visits or goal oriented visits. (N) Prevention of diarrhea with rotavirus vaccine.

Shown in each panel are the odds ratio (OR) from each individual trial per country group and the summary OR of all trials within the same country group, for the respective topic, along with their 95% confidence intervals (CIs). The summary ORs of trials within each country group were synthesized both by fixed effect model (I-V subtotal) and by random effect models (D+L subtotal). (I-V: inverse variance [fixed effects] model; D+L: DerSimonian and Laird [random effects] model).


Panel A. Bacterial infections with antibiotic prophylaxis in cirrhotic patients with upper GI bleeding




Panel B. Prevention of pre-eclampsia with antioxidants




Panel C. Prevention of proteinuric pre-eclampsia with antiplatelet agents




Panel D. Development of active tuberculosis with isoniazid in non-HIV infected persons




Panel E. Invasive fungal infections with prophylactic usage of fluconazole in very low birth weight infants




Panel F. Cardiovascular events with lipid-lowering regimens for peripheral arterial disease




Panel G. All-cause pneumonia with vaccination for preventing pneumococcal infection in adults.




Panel H. Prevention of clinical pre-eclampsia with vitamin E supplementation in pregnancy




Panel I. Prevention of GI cancers with antioxidants




Panel J. Need for caesarian section with beta-blockers for hypertension during pregnancy




Panel K. No recovery from hepatic encephalopathy with probiotics



Panel L. Sepsis in pre-term and/or low-birth weight infants with intravenous immunoglobulin



Panel M. Pre-term birth with reduced number of antenatal visits or goal oriented visits



Panel N. Prevention of diarrhea with rotavirus vaccine




Fig A2 Less developed and more developed countries where eligible randomised trials had been done. Trials conducted in African countries, western European countries, or North America and for which the exact country name could not be dissected from the Cochrane reviews are represented as Africa, Europe, and North America, respectively. USA/Canada: trials recruiting patients from both the United States and Canada; USA/Europe: trials recruiting patients from both the United States and European countries